Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Neumann

Showing results (51-60 of 301) with videos related to

Pageof 31
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 7, 2023
Author ReplyDavid D Kim, Peter J Neumann
The New England Journal of Medicine|January 19, 2017
Cost-Effectiveness Analysis 2.0Peter J Neumann, Gillian D Sanders
The American Journal of Managed Care|March 25, 2005
The impact of Medicare modernization on coverage policy: recommendations for reformSusan Bartlett Foote, Peter J Neumann
JAMA|May 26, 2018
QALYs in 2018-Advantages and ConcernsPeter J Neumann, Joshua T Cohen
Health Affairs (Project Hope)|May 9, 2007
What's more dangerous, your aspirin or your car? Thinking rationally about drug risks (and benefits)Joshua T Cohen, Peter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2012
FDA actions against health economic promotions, 2002-2011Peter J Neumann, Sarah K Bliss
The Oncologist|February 16, 2006
Do oncologists believe new cancer drugs offer good value?Eric Nadler, Ben Eckert, Peter J Neumann
JAMA|January 22, 2003
Direct-to-consumer advertising and shared liability for pharmaceutical manufacturersMichelle M Mello, Meredith Rosenthal, Peter J Neumann
Expert Review of Pharmacoeconomics & Outcomes Research|January 7, 2016
Cost-effectiveness of adherence-enhancing interventions: a systematic reviewTzahit Simon-Tuval, Peter J Neumann, Dan Greenberg
Patient Preference and Adherence|December 27, 2022
Patient and Caregiver Views on Measures of the Value of Health InterventionsDominic Voehler, Peter J Neumann, Daniel A Ollendorf
Pageof 31

Showing results (51-60 of 301) with videos related to

Sort By:
Pageof 31
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 7, 2023
Author ReplyDavid D Kim, Peter J Neumann
The New England Journal of Medicine|January 19, 2017
Cost-Effectiveness Analysis 2.0Peter J Neumann, Gillian D Sanders
The American Journal of Managed Care|March 25, 2005
The impact of Medicare modernization on coverage policy: recommendations for reformSusan Bartlett Foote, Peter J Neumann
JAMA|May 26, 2018
QALYs in 2018-Advantages and ConcernsPeter J Neumann, Joshua T Cohen
Health Affairs (Project Hope)|May 9, 2007
What's more dangerous, your aspirin or your car? Thinking rationally about drug risks (and benefits)Joshua T Cohen, Peter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2012
FDA actions against health economic promotions, 2002-2011Peter J Neumann, Sarah K Bliss
The Oncologist|February 16, 2006
Do oncologists believe new cancer drugs offer good value?Eric Nadler, Ben Eckert, Peter J Neumann
JAMA|January 22, 2003
Direct-to-consumer advertising and shared liability for pharmaceutical manufacturersMichelle M Mello, Meredith Rosenthal, Peter J Neumann
Expert Review of Pharmacoeconomics & Outcomes Research|January 7, 2016
Cost-effectiveness of adherence-enhancing interventions: a systematic reviewTzahit Simon-Tuval, Peter J Neumann, Dan Greenberg
Patient Preference and Adherence|December 27, 2022
Patient and Caregiver Views on Measures of the Value of Health InterventionsDominic Voehler, Peter J Neumann, Daniel A Ollendorf
Pageof 31